There are currently 62 active clinical trials seeking participants for Atopic Dermatitis research studies. The states with the highest number of trials for Autism participants are California, Florida, Texas and Ontario.
Effects of Abrocitinib in Subjects With Atopic Dermatitis With an Unsatisfactory Response After Treatment With Dupilumab
NCT05602207
Recruiting
This is a single-arm, open-label study that will examine the effect of abrocitinib in subjects with atopic dermatitis.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/08/2024
Locations: Inno-6050 Site 22, Birmingham, Alabama +11 locations
Conditions: Atopic Dermatitis
Register for Updates
Immunogenetic Profiling of Dupilumab for the Treatment of Atopic Dermatitis
NCT03293030
Recruiting
This is a single-arm, open-label study to examine the effect of dupilumab on the immunologic and genetic environment within atopic dermatitis skin lesions.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/06/2024
Locations: UCSF Psoriasis and Skin Treatment Center, San Francisco, California
Conditions: Atopic Dermatitis, Atopic Dermatitis Eczema, Eczema, Atopic Dermatitis and Related Conditions
Register for Updates
Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control Population
NCT06259669
Recruiting
This observational (enrollment into the registry while the pregnancy is ongoing) study is being conducted to compare the frequency of major congenital malformation (MCM)s among infants of women exposed to ruxolitinib cream during pregnancy with infants of women not exposed to ruxolitinib cream during pregnancy.
Gender:
Female
Ages:
Between 15 years and 50 years
Trial Updated:
03/04/2024
Locations: Syneos Health (remote site), Morrisville, North Carolina
Conditions: Pregnancy Related, Atopic Dermatitis
Register for Updates
Bodewell Products for the Treatment of Atopic Dermatitis
NCT05566262
Recruiting
This study aims to examine the safety and efficacy of topical application of the Bodewell eczema products
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
02/28/2024
Locations: The University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Atopic Dermatitis
Register for Updates
10 Year Registry of Children (Ages 2-17 Years) With Eczema That Have Used Pimecrolimus
NCT00568997
Recruiting
This study will examine the risk of systemic malignancies in pediatric patients with atopic dermatitis exposed to Elidel 1% cream.
Gender:
All
Ages:
Between 2 years and 17 years
Trial Updated:
02/22/2024
Locations: Registry, Philadelphia, Pennsylvania
Conditions: Atopic Dermatitis
Register for Updates
Phase 2a Study of Efficacy and Safety of OpSCF in Moderate to Severe Atopic Dermatitis
NCT06101823
Recruiting
The purpose of this study is to determine the efficacy and safety of a monoclonal antibody, OpSCF, in the treatment of adults with moderate to severe Atopic Dermatitis (Eczema). OpSCF will be compared to a placebo. OpSCF or placebo will be administered every 2 weeks for 14 weeks, and the efficacy will be assessed two weeks later. After that, subjects may choose to enter an Open Label Extension phase in which all subjects will receive OpSCF every 4 weeks for 40 additional weeks.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
02/20/2024
Locations: Cahaba Dermatology & Skin Health Center, Birmingham, Alabama +21 locations
Conditions: Atopic Dermatitis
Register for Updates
Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD)
NCT05509023
Recruiting
This is a phase IIa, randomized, double-blind, placebo-controlled, multi-center proof-of-concept (POC) study in subjects with moderate to severe Atopic Dermatitis.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/16/2024
Locations: Cahaba Dermatology Skin Health Center, Birmingham, Alabama +39 locations
Conditions: Atopic Dermatitis
Register for Updates
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
NCT00177268
Recruiting
This is a tissue, urine, and blood banking protocol for cutaneous t-cell lymphoma (CTCL), eczema, and atopic dermatitis patients for current and future research.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/16/2024
Locations: University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
Conditions: Cutaneous T-cell Lymphoma, Sezary Syndrome, Mycosis Fungoides, Eczema, Atopic Dermatitis
Register for Updates
Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis
NCT05436535
Recruiting
This is a multi-center, longitudinal study which will characterize the gene expression profiles and transcriptomic endotypes that underlie mild and moderate-severe Atopic dermatitis (AD) and will determine changes in these expression patterns and endotypes in response to standard-of-care treatment. Participants will complete up to ten scheduled study visits with assessment of topical steroid response and dupilumab response (if uncontrolled with topical steroids). Skin samples will be collected a... Read More
Gender:
All
Ages:
6 years and above
Trial Updated:
01/31/2024
Locations: University of California, San Diego: Dermatology Clinical Trials Unit, La Jolla, California +9 locations
Conditions: Atopic Dermatitis
Register for Updates
POC Study to Evaluate BSI-045B Monotherapy and BSI-045B add-on Therapy With Dupilumab in Atopic Dermatitis
NCT05932654
Recruiting
The study is a multicenter clinical trial and is designed as a proof-of-concept study to evaluate the efficacy, safety, tolerability, PK, immunogenicity, and PD of BSI-045B following SC injections, as monotherapy or as add-on therapy with dupilumab. The study will enroll patients with moderate to severe AD in 4 cohorts. There will be 2 Monotherapy Cohorts, assigned to different doses of BSI-045B: a 300 mg Cohort and a 480 mg Cohort. There will be 2 Add-on Therapy Cohorts, assigned to different... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
01/30/2024
Locations: First OC Dermatology - Fountain Valley, Fountain Valley, California +16 locations
Conditions: Atopic Dermatitis
Register for Updates
Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Atopic Dermatitis
NCT06144424
Recruiting
This Phase 2a trial will evaluate the effects of EP262 in subjects with atopic dermatitis
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
01/29/2024
Locations: Allervie Clinical Research, Birmingham, Alabama +9 locations
Conditions: Atopic Dermatitis
Register for Updates
Registry for Systemic Eczema Treatments
NCT06136767
Recruiting
The Registry for Systemic Eczema Therapies (RESET) registry is a database and biospecimen repository for patients with pediatric-onset atopic dermatitis (AD) who have used or will initiate any systemic treatment(s) for AD. The goal of the registry is to enable more efficient research recruitment and data collection as well as timely notification to enrollees about newly FDA-approved treatments for AD.
Gender:
All
Ages:
Between 1 year and 26 years
Trial Updated:
01/18/2024
Locations: Johns Hopkins University, Baltimore, Maryland
Conditions: Atopic Dermatitis
Register for Updates